Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mind Medicine (MindMed) Inc.

6.15
-0.3100-4.80%
Post-market: 6.160.0110+0.18%19:32 EDT
Volume:946.65K
Turnover:5.86M
Market Cap:464.64M
PE:-3.99
High:6.53
Open:6.46
Low:6.03
Close:6.46
Loading ...

Mind Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
Yesterday

Mind Medicine (MindMed) Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Mind Medicine Q1 EPS $(0.35) Beats $(0.38) Estimate

Benzinga
·
08 May

BRIEF-MindMed Q1 Net Income USD -23.348 Million

Reuters
·
08 May

H.C. Wainwright Sticks to Their Buy Rating for Mind Medicine (MNMD)

TIPRANKS
·
01 May

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
25 Apr

Press Release: MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Dow Jones
·
24 Apr

Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Simply Wall St.
·
23 Apr

BRIEF-Mind Medicine (Mindmed) Inc - Mindmed Enters Into First Amendment To Loan And Security Agreement - SEC Filing

Reuters
·
22 Apr

Mind Medicine (MindMed) Inc - MindMed Enters Into First Amendment to Loan and Security Agreement - SEC Filing

THOMSON REUTERS
·
22 Apr

Mind Medicine Doses First Patient in Phase 3 Trial on MM120 for Major Depressive Disorder

MT Newswires Live
·
15 Apr

BRIEF-Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd)

Reuters
·
15 Apr

Mind Medicine (MindMed) Inc - Topline Data Expected in Second Half of 2026

THOMSON REUTERS
·
15 Apr

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of Mm120 in Major Depressive Disorder (Mdd)

THOMSON REUTERS
·
15 Apr

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Business Wire
·
15 Apr

MindMed Announces New Employee Inducement Grants

Business Wire
·
25 Mar

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

MindMed Appoints Matt Wiley as Chief Commercial Officer

THOMSON REUTERS
·
17 Mar

MindMed Appoints Matt Wiley as Chief Commercial Officer

Business Wire
·
17 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar